Specialized Programs of Research Excellence (SPOREs) in Human Cancer for the Year 2008 and 2009 (P50) | Apply Online

Opportunity Summary:

The Specialized Programs of Research Excellence (SPOREs) in Human Cancer for 2008 and 2009 (P50) was a National Cancer Institute (NCI) funding opportunity designed to support large, coordinated, organ site specific cancer research programs that directly connect laboratory discoveries to clinical and population impacts. The central purpose of the SPORE mechanism is translational research that can move cancer prevention, detection, diagnosis, and treatment forward in practical ways. In this context, NCI defined translational research as work that uses knowledge of human biology to develop and test cancer-relevant interventions in people, and/or research that explains the biological reasons behind findings observed in patients with cancer or in populations at risk. The emphasis was on studies with a clear pathway to near-term benefits, including reductions in cancer incidence and mortality, rather than purely basic science without a direct route to application.

A key structural requirement of this FOA was that each application be focused on a single organ site or cancer type. While applicants could propose research across many themes (prevention through therapy, etiology through outcomes), the program had to be anchored in one defined cancer area. The announcement listed many acceptable examples, including hematologic malignancies (leukemias, lymphomas, myelomas) and solid tumors or organ system groupings such as brain, breast, gastrointestinal system, genitourinary system, gynecologic system, head and neck, lung, ovary, pancreas, prostate, skin, oral cavity and pharynx, bone and soft tissue, eye and orbit, and endocrine cancers. Institutions were encouraged to consult NCI program staff when choosing and framing the organ site focus, which reflects how SPOREs are expected to align with NCI priorities, feasibility, and the availability of clinical and research resources.

The FOA required a SPORE to be built around a minimum of four translational research projects, supported by one or more shared resource cores and complemented by both a developmental research program and a career development program. This required package was meant to ensure that the SPORE was not just a set of disconnected studies, but an integrated engine that could generate, test, and refine clinically meaningful ideas while also building the next generation of translational investigators. The developmental research component typically functions as a flexible mechanism to seed innovative pilot projects, explore emerging leads, and respond quickly to new scientific opportunities that arise during the grant period. The career development component is intended to cultivate early-stage and transitioning investigators, giving them mentorship, protected time, and access to SPORE infrastructure so they can become independent translational researchers.

Among the shared infrastructure elements, one core was explicitly required: a human cancer tissue core for the specific organ site under study. This requirement reflects the program's translational focus, since access to well-annotated human specimens is essential for validating biomarkers, understanding tumor biology in real patient samples, and linking molecular findings to clinical outcomes. The tissue core is intended to benefit multiple SPORE projects by standardizing procurement, processing, storage, quality control, annotation, and distribution of biospecimens, thereby increasing rigor and efficiency across the entire program.

Collaboration was another defining feature of the SPORE model. The FOA described SPOREs as vehicles to foster extended, long-term collaborations among laboratory scientists, clinicians, and applied researchers. Each SPORE was expected to demonstrate a robust existing research base in the chosen cancer type, strong access to appropriate patient populations (which is necessary for clinical studies, correlative science, and validation in real-world settings), and substantial institutional commitment. That institutional commitment typically implies leadership engagement, protected resources, space, recruitment support, and administrative backing to sustain multidisciplinary work beyond a single project cycle. The announcement also strongly encouraged collaborations across SPOREs (inter-SPORE work) and partnerships between SPOREs and other NIH-supported programs, aiming to create a broader network effect where tools, cohorts, methods, and discoveries can be shared and scaled.

Administratively, this opportunity was issued as a discretionary grant under the P50 center grant mechanism, with the Funding Opportunity Number PAR-08-020 and a posted date of December 3, 2008. The original and current closing date listed was September 22, 2009, with an archive date of October 23, 2009. Cost sharing or matching was not required, which is consistent with many NIH research funding mechanisms where scientific merit and programmatic fit are the primary considerations rather than institutional matching funds.

Eligibility was broad and included a wide range of organization types capable of supporting complex translational programs. Eligible applicants included public and state-controlled institutions of higher education, private institutions of higher education, nonprofits with and without 501(c)(3) status, for-profit organizations other than small businesses, small businesses, and state governments. The FOA also noted additional eligible applicants such as eligible federal agencies, regional organizations, and U.S. territories or possessions. This wide eligibility reflects the reality that translational cancer research often depends on integrated systems that can include academic centers, healthcare delivery organizations, specialized research institutes, and sometimes industry or mixed public-private collaborations, provided the applicant institution can demonstrate the necessary infrastructure, patient access, and scientific depth.

The opportunity was associated with multiple CFDA numbers in the source data (93.121, 93.397, and 93.853), which indicates that the program can intersect with several NIH/NCI funding classifications and research domains, even though the core mission here is clearly cancer-focused and administered through the NCI. For applicants and stakeholders, the practical takeaway is that this FOA supported organ-focused translational cancer centers of excellence with required projects, cores, and training components, all aimed at producing clinically meaningful advances as quickly as possible. The full announcement was referenced through the NIH Grants Guide link (http://grants.nih.gov/grants/guide/pa-files/PAR-08-020.html), and technical access issues were routed to the NIH Office of Extramural Research webmaster contacts listed in the source.

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Education Health

Next opportunity: National Cooperative Drug Discovery and Development Groups (NCDDDG) for the Treatment of Mental Disorders, Drug or Alcohol Addiction (U01/U19)

Previous opportunity: Centers Program for Research on HIV/AIDS and Mental Health (P30)

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for PAR 08 020

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (PAR 08 020) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "PAR 08 020", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.